We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
-3.84%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$546M
AUM Growth
-$31.1M
Cap. Flow
+$46.9M
Cap. Flow %
8.6%
Top 10 Hldgs %
37.26%
Holding
117
New
22
Increased
53
Reduced
27
Closed
15

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$20.3M
2
HCA icon
HCA Healthcare
HCA
+$15.4M
3
COO icon
Cooper Companies
COO
+$9.29M
4
CRL icon
Charles River Laboratories
CRL
+$9.07M
5
ZBH icon
Zimmer Biomet
ZBH
+$9.02M

Top Sells

Rank Stock Value
1
DHR icon
Danaher
DHR
+$14.6M
2
LNTH icon
Lantheus
LNTH
+$14.3M
3
WAT icon
Waters Corp
WAT
+$10.8M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$5.89M
5
SDGR icon
Schrodinger
SDGR
+$4.59M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
2 Industrials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
51
DELISTED
Merus
MRUS
$3.08M 0.56%
130,735
+62,854
+93% +$1.52M
MLTX icon
52
MoonLake Immunotherapeutics
MLTX
$1.47B
$3.04M 0.56%
53,293
-26,707
-33% -$1.47M
NEO icon
53
NeoGenomics
NEO
$2.11B
$3.02M 0.55%
245,812
+9,965
+4% +$148K
CRNX icon
54
Crinetics Pharmaceuticals
CRNX
$8.96B
$2.97M 0.54%
+100,000
New +$2.06M
ESTA icon
55
Establishment Labs
ESTA
$2.25B
$2.97M 0.54%
60,530
+2,447
+4% +$146K
SLNO
56
DELISTED
Soleno Therapeutics
SLNO
$2.95M 0.54%
+100,000
New +$605K
PHLT
57
DELISTED
Performant Healthcare Inc
PHLT
$2.94M 0.54%
1,299,385
-147,030
-10% -$373K
EVH icon
58
Evolent Health
EVH
$471M
$2.81M 0.52%
103,320
-16,172
-14% -$450K
EW icon
59
Edwards Lifesciences
EW
$53.6B
$2.77M 0.51%
+40,000
New +$3.21M
EWTX icon
60
Edgewise Therapeutics
EWTX
$4.73B
$2.71M 0.5%
473,312
+19,065
+4% +$130K
BBIO icon
61
BridgeBio Pharma
BBIO
$16.4B
$2.64M 0.48%
+100,000
New +$2.84M
BCYC
62
Bicycle Therapeutics
BCYC
$284M
$2.47M 0.45%
122,721
-49,564
-29% -$1.13M
IRON icon
63
Disc Medicine
IRON
$3.09B
$2.45M 0.45%
52,058
+2,058
+4% +$103K
AKYA
64
DELISTED
Akoya BioSciences
AKYA
$2.44M 0.45%
525,623
+54,623
+12% +$314K
LYRA
65
DELISTED
LYRA THERAPEUTICS INC
LYRA
$2.44M 0.45%
12,501
+501
+4% +$89.6K
ACAD icon
66
Acadia Pharmaceuticals
ACAD
$5.07B
$2.41M 0.44%
115,777
+15,777
+16% +$429K
NAMS icon
67
NewAmsterdam Pharma
NAMS
$3.33B
$2.3M 0.42%
249,024
+9,973
+4% +$108K
NTRA icon
68
Natera
NTRA
$45.5B
$2.25M 0.41%
50,751
-24,288
-32% -$1.24M
QTRX icon
69
Quanterix
QTRX
$139M
$2.09M 0.38%
77,087
+26,943
+54% +$667K
ABOS icon
70
Acumen Pharmaceuticals
ABOS
$181M
$2.07M 0.38%
+499,814
New +$3.09M
MIRM icon
71
Mirum Pharmaceuticals
MIRM
$6.04B
$2.06M 0.38%
65,050
+2,640
+4% +$72.3K
ARVN icon
72
Arvinas
ARVN
$580M
$2.04M 0.37%
104,117
+4,117
+4% +$101K
URGN icon
73
UroGen Pharma
URGN
$2.39B
$2.04M 0.37%
+145,311
New +$2.33M
LBPH
74
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$1.98M 0.36%
355,957
+14,370
+4% +$92.5K
ESPR
75
DELISTED
Esperion Therapeutics
ESPR
$1.96M 0.36%
1,997,071
-135,238
-6% -$196K
1 2
3
4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2023 Portfolio in Review

As of Q3 2023, Parkman Healthcare Partners held 117 positions worth $546M, down 5.4% from $577M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Parkman Healthcare Partners deployed $46.9M of net new capital in Q3 2023, opening 22 new positions and adding to 53 existing holdings. Its largest new stake was HCA Healthcare: 56,160 shares worth $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Lantheus, an estimated $14.3M trimmed.

  • Parkman Healthcare Partners's largest Q3 2023 buy was HCA Healthcare: 56,160 shares worth $13.8M.
  • Parkman Healthcare Partners added most to DexCom in Q3 2023, an estimated $20.3M increase.
  • Parkman Healthcare Partners's biggest Q3 2023 reduction was Lantheus, cutting an estimated $14.3M.
  • Parkman Healthcare Partners fully exited Danaher in Q3 2023, selling an estimated $14.6M.
  • Parkman Healthcare Partners's ten largest holdings make up 37% of its $546M portfolio in Q3 2023.
  • Parkman Healthcare Partners opened 22 new positions and closed 15 in Q3 2023.
  • Parkman Healthcare Partners's portfolio value fell 5.4% quarter-over-quarter to $546M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2023, filed 14 Nov 2023.